Cargando…
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity
RORγt is the key transcription factor controlling the development and function of CD4(+) Th17 and CD8(+) Tc17 cells. Across a range of human tumors, about 15% of the CD4(+) T cell fraction in tumor-infiltrating lymphocytes are RORγ+ cells. To evaluate the role of RORγ in antitumor immunity, we have...
Autores principales: | Hu, Xiao, Liu, Xikui, Moisan, Jacques, Wang, Yahong, Lesch, Charles A., Spooner, Chauncey, Morgan, Rodney W., Zawidzka, Elizabeth M., Mertz, David, Bousley, Dick, Majchrzak, Kinga, Kryczek, Ilona, Taylor, Clarke, Van Huis, Chad, Skalitzky, Don, Hurd, Alexander, Aicher, Thomas D., Toogood, Peter L., Glick, Gary D., Paulos, Chrystal M., Zou, Weiping, Carter, Laura L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215247/ https://www.ncbi.nlm.nih.gov/pubmed/28123897 http://dx.doi.org/10.1080/2162402X.2016.1254854 |
Ejemplares similares
-
RORgamma agonists enhance survival and memory of type 17 T cells and improve anti-tumor activity
por: Hu, Xiao, et al.
Publicado: (2015) -
Novel synthetic RORγ agonist compounds as a potential anti-tumor therapeutic approach
por: Hu, Xiao, et al.
Publicado: (2014) -
Effective Activation and Expansion of Canine Lymphocytes Using a Novel Nano-Sized Magnetic Beads Approach
por: Szopa, Iwona Monika, et al.
Publicado: (2021) -
Th17 cells have stem cell-like features and promote long-term immunity
por: Wei, Shuang, et al.
Publicado: (2012) -
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies
por: Neal, Lillian R., et al.
Publicado: (2017)